The Amazing Case of Rob F: Oligo-Metastatic NSCLC as a Truly Chronic Disease

Article

One of the issues that we've commonly discussed and debated here is the question of when a local approach like surgery and/or radaition may be appropriate for I recently saw a patient of mine who I first met more than four years ago. At that time, he was only 37 years old and had just been diagnosed with stage IIIA NSCLC with several N2 nodes involved, after having quit smoking a couple of years earlier. He had actually initiated treatment with another local oncologist, a plan of chest radiation along with concurrent weekly carbo and taxol.

Differences in Never-Smoker vs. Current/Ex-Smokers Receiving Chemo

Article

A quick point on the importance of biology over treatment. Years ago, I highlighted the results in the TRIBUTE trial of chemo with placebo or combined with erlotinib (tarceva) at the same time (biomarker study abstract here), which showed that patients with EGFR mutations had a much better survival whether they received an EGFR inhibitor or not:

Can Development of a Rash on Erbitux Predict Who Will Benefit?

Article

The improvement in median survival of 1.2 months with the monoclonal antibody to EGFR erbitux (cetuximab) in the FLEX trial that I've previously described was statistically significant, but there's plenty of room to debate whether it's really clinically significant (see prior post). What If we could add some way to refine our predictions of who will benefit from the addition of erbitux?

First Line Chemotherapy for Advanced NSCLC: An Introduction

Article

This pilot video slide presentation covers the development of our current standards for first line chemotherapy to treat advanced non-small cell lung cancer.

[powerpress]

These series will be called GRACEcasts (love it?), and we're in the process of developing a bunch of audio interviews with experts for an audio channel, and multiple video presentations, which are going to be about 10 minutes each, just little chapters at one time.

Tales from the Clinic: Anne S and her Indolent Metastatic NSCLC

Article

Let's return to what happened with Anne S., who I introduced in the last post. The highlights are that I met this woman in September of 2005, when she was 79, slowing down from many medical issues unrelated to cancer, wary about chemo, and with a cancer that was metastatic but that had progressed only minimally in the months between the initial detection of her cancer and when I first saw her. We agreed that attentive follow-up made sense.

Clinical Cases: 79 Year-Old Woman with an Indolent Metastatic NSCLC, Part 1

Article

In addition to the presentations about the evidence, I thought it might be helpful to highlight some of my own clinic cases that can illustrate how I use the principles in practice. These cases should highlight that many if not most people don't exactly follow the "classic" example, and that if we were to open the case files from most oncologists, we'd find that it's very common (and appropriate) to bend the guidelines, to individualize based on the particular issues of a specific person. And I think it may also be helpful to see the range of what's possible.

First Video Presentation Available for Download

Article

While we work on making audio and video presentations available as podcasts and on youtube, I wanted to make the initial video presentation available for people who want to see the format and have an internet connection fast enough to download a LARGE file (>80 MB) in a timely way. If you're interested, click here to download the file, using a workaround application.

Subscribe to metastatic NSCLC